Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
CD40 agonists have been investigated as a strategy to awaken the immune system against cancers. Here, the authors use a virus encoding CD40L and tumour-associated antigens to enhance innate and adaptive immunity that together with tumour targeting antibodies controls the growth of tumours in mice.
Guardado en:
Autores principales: | José Medina-Echeverz, Maria Hinterberger, Marco Testori, Marlene Geiger, Raphael Giessel, Barbara Bathke, Ronny Kassub, Fabienne Gräbnitz, Giovanna Fiore, Sonia T. Wennier, Paul Chaplin, Mark Suter, Hubertus Hochrein, Henning Lauterbach |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d593337aeba54d49978178381a7a20e5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Mechanism of pyocyanin abolishment caused by mvaT mvaU double knockout in Pseudomonas aeruginosa PAO1
por: Limin Dong, et al.
Publicado: (2020) -
Synergistic Effects of Acoustics-based Therapy and Immunotherapy in Cancer Treatment
por: Yuheng Bao, et al.
Publicado: (2021) -
Single-molecule study on histone-like nucleoid-structuring protein (H-NS) paralogue in Pseudomonas aeruginosa: MvaU bears DNA organization mode similarities to MvaT.
por: Ricksen S Winardhi, et al.
Publicado: (2014) -
Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
por: Fan Yang, et al.
Publicado: (2021) -
Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles
por: Jing Qi, et al.
Publicado: (2021)